eXmoor Pharma

Bristol, UK
Cell Therapy AAV
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
78.7
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (3) ○ EMA GMP ✓ MHRA GMP (1)

Quick Facts: eXmoor Pharma

Signal Score
78.7/100 (as of 2026-04-29)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Bristol, UK
Modalities
Cell Therapy, AAV
Active Programs
No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About eXmoor Pharma

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
MHRA GMP Certificates1 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
1 manufacturing site: Bristol, UK
Modalities: Cell Therapy, AAV
Capacity assessment: 60.0/100
Sites: Bristol, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press3 articles
1 manufacturing site: Bristol, UK
Modalities: Cell Therapy, AAV
Capacity assessment: 60.0/100

MHRA GMP Compliance 1 certificates

2025-11
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA(IMP) 32954 Insp GMP/IMP 32954/36082496-0002[I] EXMOOR PHARMA CONCEPTS LTD BRISTOL BS34 5TA 2025-11-12 COMPLIANT
Source: MHRA GMDP Database · Retrieved May 20, 2026

Recent News 3 articles

partnership 2026-04-10
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing - BioPharma APAC
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing  BioPharma APAC
Source →
general 2026-03-06
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer - Pharmafile
eXmoor Pharma appoints Manuel Balbuena as Chief Commercial Officer  Pharmafile
Source →
general 2026-03-03
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer - Contract Pharma
eXmoor Pharma Appoints Manuel Balbuena Chief Commercial Officer  Contract Pharma
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs → AAV CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Cell and Gene Therapy Catapult
Stevenage, UK
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV
Danaher (CGT Portfolio)
Washington, DC
Signal Score: 81.5
Cell Therapy, AAV, mRNA
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral